Angelo Y Luciano1, H A Jinnah2, Ronald F Pfeiffer1, Daniel D Truong3, Martha A Nance4, Mark S LeDoux5. 1. Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA. 2. Departments of Neurology, Human Genetics, and Pediatrics, School of Medicine, Emory University Atlanta, GA, USA. 3. Parkinson's & Movement Disorder Institute, Fountain Valley, CA, USA. 4. Struthers Parkinson's Center, Golden Valley, MN, USA. 5. Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA. Electronic address: mledoux@uthsc.edu.
Abstract
BACKGROUND: Many cases of myoclonus-dystonia (M-D) are due to mutations in SGCE (DYT11). For the majority of patients, myoclonus is relatively more severe than dystonia and can lead to significant functional disability. Deep brain stimulation has been chosen as a treatment option in some patients given that M-D often responds poorly to oral pharmacotherapy. METHODS: Two siblings with M-D due to the same SGCE deletion mutation were evaluated with the Global Dystonia Rating Scale (GDRS), Fahn-Marsden Rating Scale (FM) and Unified Myoclonus Rating Scale (UMRS) on and off tetrabenazine. RESULTS: Both subjects showed marked improvement in myoclonus and mild-to-moderate improvement in dystonia with tetrabenazine. In addition, the response to tetrabenazine has been sustained for years. CONCLUSIONS: A therapeutic trial of tetrabenazine should be considered in patients with M-D, especially before consideration of deep brain stimulation. An adequately powered multi-center, double-blind study of tetrabenazine will be required to determine the relative contributions of tetrabenazine therapy to myoclonus, dystonia, quality of life, and activities of daily living in patients with M-D.
BACKGROUND: Many cases of myoclonus-dystonia (M-D) are due to mutations in SGCE (DYT11). For the majority of patients, myoclonus is relatively more severe than dystonia and can lead to significant functional disability. Deep brain stimulation has been chosen as a treatment option in some patients given that M-D often responds poorly to oral pharmacotherapy. METHODS: Two siblings with M-D due to the same SGCE deletion mutation were evaluated with the Global Dystonia Rating Scale (GDRS), Fahn-Marsden Rating Scale (FM) and Unified Myoclonus Rating Scale (UMRS) on and off tetrabenazine. RESULTS: Both subjects showed marked improvement in myoclonus and mild-to-moderate improvement in dystonia with tetrabenazine. In addition, the response to tetrabenazine has been sustained for years. CONCLUSIONS: A therapeutic trial of tetrabenazine should be considered in patients with M-D, especially before consideration of deep brain stimulation. An adequately powered multi-center, double-blind study of tetrabenazine will be required to determine the relative contributions of tetrabenazine therapy to myoclonus, dystonia, quality of life, and activities of daily living in patients with M-D.
Authors: Katja Ritz; Barbera Dc van Schaik; Marja E Jakobs; Antoine H van Kampen; Eleonora Aronica; Marina A Tijssen; Frank Baas Journal: Eur J Hum Genet Date: 2010-12-15 Impact factor: 4.246
Authors: Kathryn J Peall; Daniel J Smith; Manju A Kurian; Mark Wardle; Adrian J Waite; Tammy Hedderly; Jean-Pierre Lin; Martin Smith; Alan Whone; Hardev Pall; Cathy White; Andrew Lux; Philip Jardine; Narinder Bajaj; Bryan Lynch; George Kirov; Sean O'Riordan; Michael Samuel; Timothy Lynch; Mary D King; Patrick F Chinnery; Thomas T Warner; Derek J Blake; Michael J Owen; Huw R Morris Journal: Brain Date: 2013-01 Impact factor: 13.501
Authors: Annelieke R Müller; Marion M M G Brands; Peter M van de Ven; Kit C B Roes; Martina C Cornel; Clara D M van Karnebeek; Frits A Wijburg; Joost G Daams; Erik Boot; Agnies M van Eeghen Journal: Neurology Date: 2021-01-27 Impact factor: 9.910